It’s official folks.
The FDA has granted full approval to the Pfizer COVID-19 jab.
However, it’s still a medical experiment.
And that’s what I’ll continue to call it.
If you missed the news this morning, the FDA made their grandiose announcement:
— Disclose.tv (@disclosetv) August 23, 2021
From the FDA:
Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.
“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Acting FDA Commissioner Janet Woodcock, M.D. “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”
High standards for safety, effectiveness, and quality?
It’s interesting that Acting FDA Commissioner Janet Woodcock said that about the Pfizer COVID-19 jab.
Is that what she said about OxyContin and Fentanyl?
Woodcock approved those and allowed an opioid epidemic to ravage the United States.
However, researchers made ominous warnings about the Pfizer COVID-19 jab.
The Francis Crick Institute of the United Kingdom conducted a study of the experimental injection.
Listen to what Dr. David Bauer says here:
…Wiping out natural immune system by drastically lowering neutralising antibodies, making recipients dependent on booster shots in perpetuity pic.twitter.com/ttBu2iNTeuhttps://t.co/wmHgYELJxB https://t.co/oCOOYTzq3e
— JOY K MOORE (@2NjoyMore) August 19, 2021
Recipients of the Pfizer jab have LOWER amounts of neutralizing antibodies.
Yet, he still advocates boosters for vulnerable groups.
But that’s the game plan.
They want your body dependent on indefinite boosters.
The Pfizer jab destroys your T cells and weakens your immune system.
That leaves you more susceptible to COVID-19 and other contagious diseases.
And with a weakened immune system, your body will have a tougher time fighting off invading pathogens.
Great job Pfizer.
Pfizer vaccine destroys T cells, weakens the immune system – study – [Natural News]: A study from the Francis Crick Institute in the United Kingdom has found that the Pfizer-BioNTech Wuha… https://t.co/dbRjYgMhGV pic.twitter.com/gPzCiU0ssK
— Matthew James (@mattjamesmedium) August 22, 2021
— Intentional Money (@GrahamJBarnes) August 15, 2021
Mint shared these findings:
US drugmaker Pfizer Inc.’s covid-19 vaccine generated fewer antibodies against the Delta variant of the novel coronavirus now prevalent in India compared to other variants, new research showed, a significant development as the country plans to include the vaccine in its mass immunization programme.
The variant, which was found first in India in October 2020, has now spread to 45 countries.
The study by the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre published in the medical journal Lancet also showed the antibody levels declined with increasing age and over time.
Scientists analysed antibodies in the blood of 250 healthy people who received either one or two doses of the Pfizer-BioNTech covid vaccine up to three months after their first dose. Using a new, highly accurate high throughput viral neutralization assay developed at the Crick Institute, they tested the ability of so-called ‘neutralizing antibodies’ to block the entry of the virus into cells against five different variants of SARS-CoV-2—the original strain first discovered in Wuhan, China, which was the dominant strain in Europe during the first wave in April 2020 (D614G); B.1.1.7, the variant first discovered in Kent, UK (Alpha); B.1.351, the variant first discovered in South Africa (Beta); and B.1.617.2, the newest variant of concern, first discovered in India (Delta).
They then compared concentrations of these neutralizing antibodies among all variants. Scientists found that in people who had been fully vaccinated with two doses of the Pfizer-BioNTech vaccine, levels of neutralizing antibodies were more than five times lower against the B.1.617.2 variant when compared to the original strain upon which current vaccines are based.
Importantly, this antibody response was even less in people who had received just one dose. Among them, 79% had a quantifiable neutralizing antibody response against the original strain, but this fell to 50% for B.1.1.7, 32% for B.1.617.2, and 25% for B.1.351. The researchers also found that after just one dose, people are less likely to develop antibody levels against the B.1.617.2 (Delta) variant as high as those seen against the previously dominant B.1.1.7 (Alpha) variant.
The Daily Expose also reported:
T cells are immune cells that are able to target specific foreign particles – they are most commonly studied in relation to their ability to fight cancer and infectious diseases, but they are also essential for other aspects of the body’s immune response.
There are two types of T cells: killer T cells and helper T cells. Killer T cells attack cells that have already been infected by foreign particles, whilst helper T cells assist other cells to develop killer cells and stimulate other cells to create neutralizing antibodies.
The study from the Francis Crick Institute focused on the neutralising antibodies which are created by T cells. It analyzed whether the Pfizer vaccine helps the T cells create enough antibodies to fight off Covid-19 and associated variants of the virus.
The study – conducted by the Francis Crick Institute in collaboration with the British National Institute for Health Research – showed that the Pfizer Covid-19 vaccine produced fewer neutralising antibodies against Covid-19 and other variants.
Scientists analyzed antibodies in the blood of 250 healthy people who received either a single or both doses of the Pfizer Covid-19 vaccine up to three months after their first dose.
The researchers used a test developed by the Francis Crick Institute to figure out the ability of the neutralising antibodies to prevent the entry of the Covid-19 variants.
The study revealed that only 50 percent of the people who received a single dose of the Pfizer vaccine had a quantifiable neutralizing antibody response against the alpha variant of Covid-19. Additionally, this number decreased to just 32 percent and 25 percent for the delta and beta variants, respectively.
Among all variants, fewer antibodies were generated the older the individual receiving the vaccine and those with weaker immune systems. Considering the vaccine’s ability to destroy T cells and weaken the immune system even further, getting vaccinated could cause damage to many people, especially those who have compromised immune systems.